6 results about "Botulinum neurotoxin" patented technology

Products, pharmaceutical compositions, methods of use, and kits are provided for treating a patient suffering from botulinum neurotoxin intoxication. Featured are single-domain variable heavy-chain (VHH) polypeptides (antibodies) that target and neutralize the light chain (LC) protease domains of botulinum neurotoxin (BoNT), i.e., BoNT LC / A and BoNT LC / B, and that advantageously provide late and post-exposure therapy for botulism patients. The LC / A toxin-binding and LC / B toxin-binding VHH polypeptides, which can be recombinantly produced, specifically bind to the LCs of the botulinum neurotoxins to inhibit toxin activity and treat intoxication.

Provided are a composition for stabilizing botulinum neurotoxin, a botulinum neurotoxin formulation including the same, and a polypeptide for use therein.

Methods for the isolation and purification of a botulinum neurotoxin protein (BONT) or a polypeptide comprising a BONT receptor-binding domain from a solution are disclosed here. The method comprises contacting the solution containing the protein or polypeptide with a matrix bound to it by a non-toxic non-hemagglutinin (NTNHA) under appropriate conditions for binding, washing the matrix to remove unbound materials, and eluting the protein or polypeptide with a solution that dissociates the bound protein from the NTNHA. Appropriate conditions for binding are a pH less than 7.5 (e.g., 6). Appropriate conditions for dissociation are a pH greater than or equal to 7.5 (e.g., 8). Specific compositions for the methods are also described.

A botulinum neurotoxin serotype E (BoNT / E) for use in treating a disorder or a cosmetic condition, wherein the BoNT / E provides a maximum inhibition of neurotransmitter secretion from a target cell or tissue 13 days or less after administration to a human subject and the inhibition is reduced but is greater than 25% at day 14 following administration. A method for treating a disorder or a cosmetic condition, the method comprising administering the aforementioned BoNT / E.

The invention is directed to treatment of limb spasticity using a modified botulinum neurotoxin A (BoNT / A) comprising a BoNT / A light-chain and translocation domain, and a BoNT / B receptor binding domain (HC domain). Also provided are unit dosage forms of said modified BoNT / A and corresponding kits.

This document discloses clostridial neurotoxin (BoNT) or SNARE cleavage homolog variants, constructs, and methods of use thereof. The BoNT or SNARE cleavage homolog variants may include substitutions, deletions, or insertions of one or more amino acids or domains in the light chain.